MedPath

To explore the treatment of psoriasis with sleep disorder by cooling blood and calming nerves: a randomized controlled trial

Phase 1
Conditions
Psoriasis
Registration Number
ITMCTR2100005257
Lead Sponsor
Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Psoriasis vulgaris was diagnosed and met the criteria of syndrome differentiation;
2. Mild and moderate sleep disorders, i.e. those with Pittsburgh sleep quality index (PSQI) score of 7 ~ 16;
3. Aged 18 to 65 years, regardless of nationality, gender and nationality;
4. Unlimited gender;
5. Voluntarily sign informed consent.

Exclusion Criteria

1. Critically ill subjects, subjects with acute diseases and subjects with mental disorders;
2. Persons with infection, pregnancy, childbirth, trauma and other stress states;
3. Those who use other drugs at the same time during treatment and cannot strictly implement the treatment plan;
4. Subjects who are allergic or intolerant to the drugs used in this study;
5. Previous or current subjects have any systemic diseases or other active skin diseases that may affect the research results;
6. The subjects had systematically applied glucocorticoids, immunosuppressants and retinoic acid preparations in recent 1 month, and used photochemotherapy and other local treatments within 2 weeks;
7. Used a research drug or participated in any research project in the first 30 days.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pittsburgh sleep quality index score;Psoriasis area and severity index score;
Secondary Outcome Measures
NameTimeMethod
Hamilton Anxiety Scale score;Traditional Chinese Medicine syndrome score;Dermatology quality of life scale score;Pruritus score;
© Copyright 2025. All Rights Reserved by MedPath